Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma.

ABSTRACT: Glioblastoma multiforme (GBM) has a global occurrence of 0.59 to 3.69 per one lakh people. Palbociclib (Palbo), an inhibitor of CDK4 (cyclin dependent kinase) and CDK6, is used for treating cancer. Palbo showed a limited therapeutic effect in brains of transgenic mice after oral administration. Further, studies on P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) knock-out mice showed that P-gp and BCRP (efflux transporters) restrict Palbo's permeability across the blood-brain barrier (BBB). Hence, the clinical usefulness of Palbo for treating GBM is limited. Palbociclib-loaded nanoparticles of albumin (Nps-Bsa-Palbo) and palbociclib-loaded nanoparticles of albumin conjugated with Polysorbate 80 (Nps-Bsa-Palbo-Ps-80) were formulated and optimized using Design Expert^®

SUBMITTER: Kurawattimath V 

PROVIDER: S-EPMC12322058 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature